Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader markets were down significantly on the day at that time, including the SPDR S&P Biotech ETF (NYSEMKT: XBI), which was down 4.4%. The interesting news for Summit was that two insiders exercised warrants on Summit's stock yesterday, which most interpreted as being highly bullish. What is notable is that the Co-CEOs exercised these warrants, forcing them to buy $6.3 million worth of shares, about four and a half years before the warrants' expiration in December of 2029.